SAN FRANCISCO, CA, UNITED STATES – Jan 22, 2020 – Notable, which is redefining cancer treatment with a clinically validated platform that rapidly advances drug development, is currently enrolling patients in its new observational clinical trial. The trial...
APX3330, a First-in-Class Ref-1 Inhibitor for Diabetic Ocular Diseases Affecting the Retina, Added to Ocuphire Portfolio of Ophthalmic Drug Candidates Data from Two Recently Completed Nyxol® Phase 2b Studies Accepted for Presentation at ARVO 2020 Conference FARMINGTON...
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that both batches of the company’s manufactured...
NEW YORK, Jan. 21, 2020 /PRNewswire/ — Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing new generation therapies for dermatological and immunological disorders such as atopic dermatitis, psoriasis, asthma and...
Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focused on commercializing excimer laser systems to treat vascular and dermatological diseases, announces approval from the U.S. Food and Drug Administration (FDA) that the Company has provided sufficient...
Email
Text